Amarin Weakness Due to FDA Requirements and 3 Stock Analyses to Track

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Skyworks Solutions Inc. (NASDAQ:SWKS):  Following management comments regarding near-term trends in the smartphone market, UBS said that Skyworks Solutions Inc. is weak. However, they believe that the trends, such as share gains, LTE, and increased smartphone content remain intact. The firm reiterates their Buy rating and would use weakness as a buying opportunity.

Don’t Miss: Why is Walmart Dumping Kindle?

QUALCOMM Incorporated (NASDAQ:QCOM): Piper said Skyworks (NASDAQ:SWKS) should have no impact on Qualcomm Incorporated (NASDAQ:QCOM) or anything Apple (NASDAQ:AAPL) related.  They remain comfortable with the iPhone 5′s content. Shares are Buy rated.

Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR): After Aetna (NYSE:AET) issued a policy bulletin concerning Questcor Pharmaceuticals, Inc.’s(NASDAQ:QCOR) Acthar Gel, Ladenburg believes it it is a bit confusing and poses some uncertainty. The firm is encouraged, however, that Questcor expects the policy to have little impact on their business. Ladenburg  anticipates that Questcor can, over time, reduce the risk of reimbursement. The firm thinks the market reaction was overdone and maintains a Buy rating on their stock.

Amarin Corporation PLC. (NASDAQ:AMRN):  Leerink said that Amarin’s weaknesses may be due to the new Federal Drug Administration’s draft guidance requirements for generic forms of Lovaza. The firm views the news as marginal and continues to believe Vascepa has a decent chance of obtaining exclusivity on their new chemical entity.  Shares are Outperform rated at $27.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business